Sensei Biotherapeutics, Inc.
FTHNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for FTH. That does not mean none is planned.
Get an email about FTH's next catalysts
Track Sensei Biotherapeutics (FTH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (regulatory event).See the timeline
1 upcoming, 2 past
Regulatory Decision - PIKTOR
For Advanced/recurrent endometrial cancer (PAM pathway alteration); HR+/HER2- breast cancer. Faeth Therapeutics reported Q3 2026 results and operational updates, including FDA Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer. Topline Phase 2 PIK-201 data are expected by year-end, with preclinical breast cancer data presented at ESMO 2026.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SNS-101 (anti-VISTA) | Phase 2 | Solid Tumor, Adult | - | - |
Frequently asked questions
What is in Sensei Biotherapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Sensei Biotherapeutics, Inc.'s (FTH) pipeline across Phase 2. Its lead program is SNS-101 (anti-VISTA) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sensei Biotherapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Sensei Biotherapeutics, Inc. (FTH) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track FTH biotech catalysts?β
Add FTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sensei Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
